LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q4 2023 Earnings Conference Call February 27, 2024 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chief Executive Officer Dave Roberts - President Conference Call Participants Suraj Kalia - Oppenheimer Daniel Stauder - JMP Securities Michael Petusky - Barrington Research James Sidoti - Sidoti & Co. Aaron Wukmir - Lake Street Capital Markets Operator Welcome to the LeMaitre Vascular Q4 2023 Financial Results Conference Call. A ...

Sales by Device Type Sales by Physician User #1 or #2 Share in 9 of 12 Markets $150 $200 Organic Inorganic (第) | Distributor Buyouts 136 reps at 12/31/23: +4% vs. 12/31/22 • Primary Criterion: Distributor with high sales Norway New Zealand Finland Singapore Korea Malaysia Thailand % of WW Sales That Products Approved in Geography Represent Approved Submitted Weighted Average Price Increase Price Increase Drivers • Differentiated products • $38K average annual purchase per hospital eMaitre® Win* (16) Loss (8 ...

Exhibit 99.1 LeMaitre Q4 2023 Financial Results BURLINGTON, MA, February 27, 2024 - LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2023 results, announced a $0.16/share quarterly dividend and provided guidance. Q4 2023 Financial Results Bovine patches (+18%), allografts (+52%), valvulotomes (+12%), carotid shunts (+16%) and distributed porcine patches drove Q4 sales. EMEA sales increased 21%, the Americas 20% and APAC 11%. The gross margin increased to 68.1% ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-2825458 ...

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q3 2023 Earnings Conference Call November 1, 2023 5:00 PM ET Company Participants Joseph Pellegrino - Chief Financial Officer George LeMaitre - Chief Executive Officer David Roberts - President Conference Call Participants Brooks O’Neil - Lake Street Capital Markets LLC Michael Petusky - Barrington Research Associates, Inc. James Sidoti - Sidoti & Company LLC Suraj Kalia - Oppenheimer & Co. Inc. Michael Sarcone - Jefferies Group LLC Scott Henry - ROTH Capital Partners, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-2825458 (Sta ...

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q2 2023 Earnings Conference Call August 1, 2023 5:00 PM ET Company Participants Joseph Pellegrino - Chief Financial Officer David Roberts - President Conference Call Participants Brett Fishbin - KeyBanc Capital Markets Inc. Aaron Wukmir - Lake Street Capital Markets Michael Petusky - Barrington Research Associates, Inc. Operator Welcome to the LeMaitre Vascular Q2 2023 Financial Results Conference Call. As a reminder, today’s call is being recorded. At this time, I woul ...

FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-2825458 (St ...

Financial Data and Key Metrics Changes - Q1 2023 sales were $47.1 million, an increase of 19% on a reported basis and 22% organically compared to Q1 2022 [16] - Gross margin for Q1 2023 was 65.6%, flat compared to the prior year, with guidance for a full-year gross margin of 65% [16][17] - Operating income for Q1 2023 was $7.9 million, reflecting an operating margin of 17% [18] - Operating expenses increased by 28% in Q1 compared to the prior year, primarily due to higher selling commissions and increased headcount [18][19] - The company expects EPS growth excluding special charges of 17% for the full year [19] Business Line Data and Key Metrics Changes - Valvulotomes sales increased by 29%, carotid patches by 17%, bovine grafts by 22%, allografts by 42%, and carotid shunts by 18% [3] - The addition of the Aziyo product line is expected to decrease gross margin by about 0.5% [17][20] - The company anticipates $3.5 million to $4 million in sales from the Aziyo distribution agreement for the year [27] Market Data and Key Metrics Changes - Sales in the Americas increased by 21%, EMEA by 17%, and APAC by 6% [3] - The company reported a 14% increase in credit card swipes in U.S. hospitals, indicating a strong recovery in procedure volumes [25] Company Strategy and Development Direction - The company is expanding its presence in Asia Pacific, with a new office in Seoul and plans to sell directly to Thai hospitals [5] - The company aims to end the year with 135 to 140 sales representatives, up from 128 [4][35] - The management is focused on leveraging the larger sales force and addressing supply chain disruptions to improve operational efficiency [17][36] Management Comments on Operating Environment and Future Outlook - Management noted that the growth was driven by an improving macro environment and increased procedure volumes as hospitals return to pre-COVID staffing levels [10] - The company expects some normalization in hospital procedure volumes over time, which may moderate sales growth [27] - Management expressed confidence in the pricing power and ability to implement price increases without significant pushback from customers [70] Other Important Information - Regulatory costs increased by 47% in Q1 as the company continues to work on obtaining MDR CE marks [19] - The company reported cash flow from operations of $2.28 million for the quarter [83] Q&A Session Summary Question: What were the key drivers of sales performance in the Americas and EMEA? - Management highlighted a significant increase in hospital activity, with a 14% rise in credit card swipes in U.S. hospitals, indicating strong procedural recovery [25] Question: How does the company expect pricing and volume trends to evolve? - Management indicated that while pricing may not sustain a 13% increase every quarter, they expect continued robust pricing and some normalization in procedure volumes [27] Question: Can you quantify the impact of Omniflow backorders on Q1 performance? - Management reported a reduction in Omniflow backorders from $800,000 at the beginning of the year to $400,000 by the end of Q1, indicating improvement [29] Question: What is the outlook for the Aziyo product line? - The company expects to generate $800,000 in sales from the Aziyo product line in Q2 and $3.8 million for the full year, with a 50% gross margin [14][57] Question: How does the company view pricing power in the current environment? - Management noted minimal pushback on recent price increases, attributing this to supply chain dynamics and inflationary pressures in the market [70]

2,022 Net income as reported $22,943 $17,934 $ Interest (income) expense, net (629) 1,103 (986) Amortization and depreciation expense 4,324 5,416 8,224 9,475 9,433 Provision for income taxes 5,501 3,745 6,136 7,380 6,854 EBITDA $32,139 $26,397 $45,784 $35,937 LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) NON-GAAP FINANCIAL MEASURES (amounts in thousands) (unaudited) $ 26,829 3,107 ହ 29,936 $ 0.93 0.14 $ 1.07 Reconciliation between GAAP and Non-GAAP EBITDA a LeMaitre® LMAT Investor Presentation YEARS 1983-2023 $26, ...